Breaking News, Collaborations & Alliances

Amarantus, Anavex in Alzheimer’s Biomarker Pact

Will use LymPro test to evaluate lead drug candidate combination

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amarantus BioScience and Anavex Life Sciences Corp. have entered a biomarker services agreement under which Amarantus will evaluate the pharmacodynamic effect of a lead drug candidate combination on the expression of the biomarker CD69 using its Alzheimer’s blood diagnostic LymPro Test.   The drugs, ANAVEX 2-73 and ANAVEX PLUS, which combines ANAVEX 2-73 with donepezil (Aricept), are Anavex’ lead drug candidate and drug candidate combination, respectively, for Alzheimer’s disea...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters